Please assess the completion status of the following clinical trial:

Trial Title: Glargine Versus NPH in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus and chronic kidney disease secondary to diabetic nephropathy in stages 3 and 4 (moderate and severe nephropathy, corresponding to glomerular filtration rate of 15-59 ml/min/1.73m²) will be included in the study.~Exclusion Criteria:~* Patients with systemic neoplasias,~* HIV, chronic kidney disease or nephropathy from other etiologies,~* severe psychiatric disorders~* pregnant women.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glargine insulin (Type: EXPERIMENTAL): This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
- NPH insulin (Type: ACTIVE_COMPARATOR): This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH.

Based on this trial design, predict the completion outcome and termination type (if applicable).